Do results of the EORTC dummy run predict quality of radiotherapy delivered within multicentre clinical trials?

European Journal of Cancer

Volumn 48, Issue 17, 2012, Pages 3232-3239

  Fairchild, A ^a,b   Collette, L ^b   Hurkmans, C W ^c   Baumert, B ^d   Weber, D C ^e   Gulyban, A ^f   Poortmans, P ^g  

^a CROSS CANCER INSTITUTE   (Canada)

^b EORTC DATA CENTER   (Belgium)

^c CATHARINA HOSPITAL   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g Institute Verbeeten   (Netherlands)

Author keywords

Dummy run; EORTC; Multicentre clinical trials; Quality assurance; Radiation therapy; ROG

Indexed keywords

ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL (TOPIC); CORRELATION ANALYSIS; DUMMY RUN; FISHER EXACT TEST; HEALTH CARE QUALITY; HUMAN; INDIVIDUAL CASE REVIEWS; MANTEL HAENSZEL TEST; METHODOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY CONTROL; RISK;

HUMANS; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; QUALITY ASSURANCE, HEALTH CARE; RADIOTHERAPY;

EID: 84868214712     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.06.002     Document Type: Article

References (28)

1. S. Bentzen, J. Bernier, and J. Davis Clinical impact of dosimetry quality assurance programmes assessed by radiobiological modelling of data from the thermoluminescent dosimetry study of the EORTC Eur J Cancer 36 5 2000 615 620
2. R. Abrams, K. Winter, and W. Regine Failure to adhere to protocol-specified radiation therapy guidelines was associated with decreased survival in RTOG 9704: a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas Int J Radiat Oncol Biol Phys 82 2 2012 809 816
3. L. Peters, B. O'Sullivan, and J. Giralt Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02 J Clin Oncol 28 18 2010 2996 3001
4. D. Weber, P. Poortmans, and C. Hurkmans Quality assurance for prospective EORTC radiation oncology trials: the challenges of advanced technology in a multicentre international setting Radiother Oncol 100 1 2011 150 156
5. M. Bolla, H. Bartelink, and G. Garavaglia EORTC guidelines for writing protocols for clinical trials of radiotherapy Radiother Oncol 36 1 1995 1 8
6. A. Fairchild, R. Bar-Deroma, and L. Collette Development of clinical trial protocols involving advanced radiation therapy techniques: the European Organisation for Research and Treatment of Cancer Radiation Oncology Group approach Eur J Cancer 48 7 2012 1048 1054
7. P. Poortmans, F. Ataman, and J. Davis Quality assurance in the EORTC phase III randomised 'boost vs no boost' trial for breast conserving therapy: comparison of the results of two individual case reviews performed early and late during the accrual period Radiother Oncol 76 3 2005 278 284
8. V. Kouloulias, P. Poortmans, and J. Bernier The Quality Assurance programme of the Radiotherapy Group of the European Organization for Research and Treatment of Cancer (EORTC): a critical appraisal of 20 years of continuous efforst Eur J Cancer 39 4 2003 430 437
9. A. Dusserre, G. Garavaglia, J.-Y. Giraud, and M. Bolla Quality assurance of the EORTC radiotherapy trial 22863 for prostatic cancer: the dummy run Radiother Oncol 36 1995 229 234
10. E. Musat, E. Roelofs, and R. Bar-Deroma Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: first evaluation of quality of radiotherapy planning Radiother Oncol 95 2 2010 218 224
11. O. Matzinger, P. Poortmans, and J.-Y. Giraud Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: dummy run and individual case review Radiother Oncol 90 2009 285 290
12. B. Baumert, M. Brada, and J. Bernier EORTC 22972-26991/MRC BR10 trial: fractionated stereotactic boost following conventional radiotherapy of high grade gliomas. Clinical and quality-assurance results of the stereotactic boost arm Radiother Oncol 88 2008 163 172
13. F. Ataman, P. Poortmans, and R. Stupp Quality assurance of the EORTC 26981-22981/NCIC CE3 intergroup trial on radiotherapy with or without temozolamide for newly-diagnosed glioblastoma multiforme: the individual case review Eur J Cancer 40 11 2004 1724 1730
14. V. Kouloulias, J.-Y. Giraud, and B. Davis Quality assurance of the 22961 EORTC trial. A phase III study of the optimal combination of hormonal adjuvant treatment by LHRH analogue and radiation therapy for the management of locally advanced prostate cancer: the dummy run Radiother Oncol 73 2004 11 20
15. C. Hurkmans, J. Borger, E. Rutgers, and G. van Tienhoven Quality assurance of axillary radiotherapy in the EORTC AMAROS trial 10981-22023: the dummy run Radiother Oncol 68 2003 233 240
16. P. Poortmans, V. Kouloulias, and J. Venselaar Quality assurance of EORTC trial 22922-10925 investigating the role of internal mammary-medial supraclavicular irradiation in stage I-III breast cancer: the individual case review Eur J Cancer 39 2003 2035 2042
17. V. Kouloulias, J.-F. Bosset, and G. van Tienhoven Quality assurance in the EORTC 22921 trial on preoperative radiotherapy with or without chemotherapy for resectable rectal cancer: evaluation of the individual case review procedure Eur J Cancer 38 2002 1849 1856
18. J. Davis, B. Reiner, and A. Dusserre Quality assurance of the EORTC trial 22911. A phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma: the dummy run Radiother Oncol 64 2002 65 73
19. Y. Lievens, P. Poortmans, and W. van den Bogaert A glance on quality assurance in EORTC study 22922 evaluating techniques for internal mammary and medial supraclavicular lymph node chain irradiation in breast cancer Radiother Oncol 60 2001 257 265
20. P. Poortmans, J. Venselaar, and H. Struikmans The potential impact of treatment variations on the results of radiotherapy of the internal mammary lymph node chain: a quality-assurance report on the dummy run of EORTC Phase III randomized trial 22922-10925 in Stage I-III breast cancer Int J Radiat Oncol Biol Phys 49 5 2001 1399 1408
21. J.-F. Valley, J. Berner, and P.-A. Tercier Quality assurance of the EORTC radiotherapy trial 22931 for head and neck carcinomas: the dummy run Radiother Oncol 47 1998 37 44
22. G. Van Tienhoven, B. Mijnheer, H. Bartelink, and D. Gonzalez Quality assurance of the EORTC trial 22881-10882: boost versus no boost in breast conserving therapy. An overview Strahlenther Onkol 173 4 1997 201 207
23. G. Van Tienhoven, N. van Bree, and B. Mijnheer Quality assurance of the EORTC trial 22881-10882: assessment of the role of the booster dose in breast conserving therapy - the dummy run Radiother Oncol 20 1991 290 298
24. M. Deutsch, J. Bryant, and G. Bass Radiotherapy review on national surgical adjuvant breast and bowel project phase III breast cancer clinical trials: is there a need for submission of portal/simulation films? Am J Clin Oncol 22 6 1999 606 608
25. P. Poortmans, V. Kouloulias, and G. van Tienhoven Quality assurance in the EORTC randomized trial 22922/10925 investigating the role of irradiation of the internal mammary and medial supraclavicular lymph node chain Strahlenther Onkol 182 2006 576 582
26. G. Ibbott, D. Followill, and A. Molineu Challenges in credentialing institutions and participants in advanced technology multi-institutional clinical trials Int J Radiat Oncol Biol Phys 71 Suppl. 1 2008 S71 S75
27. B. Aleman, T. Girinsky, and R. van der Maazen Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphome (EORTC 20884) Int J Radiat Oncol Biol Phys 63 4 2005 1184 1190
28. C. Clark, E. Miles, and M. Urbano Pre-trial quality assurance processes for an intensity-modulated radiation therapy (IMRT) trial: PARSPORT, a UK multicentre Phase III trial comparing conventional radiotherapy and parotid-sparing IMRT for locally advanced head and neck cancer Br J Radiol 82 2009 585 594